BRIEF—eXmoor enlisted to help manufacture Imophoron's RSV candidate

Cell and gene therapy manufacturing company eXmoor pharma and vaccine developer Imophoron have agreed a strategic process development partnership that includes a future GMP manufacturing route.

Under the agreement, eXmoor will firstly develop a scalable and commercializable manufacturing platform for Imophoron’s vaccine technology.

This platform will be optimized initially for Imophoron’s lead candidate vaccine, targeting respiratory syncytial virus.

Imophoron is developing its ADDomer platform to rapidly generate vaccine candidates targeting a range of different diseases that can be administered by a variety of routes, including intranasal and intramuscular.

Notably, it has demonstrated the thermostability of its vaccine candidates, hence removing the requirement for the sub-temperature storage of alternative vaccine technologies, including those that are mRNA based.

This would potentially allow global distribution with no cold chain whatsoever.